Evolva Holding SA (SIX: EVE)

https://www.evolva.com

Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people's lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications. *

	Start	2009-11-04 renamed date ca
	Group	Lallemand (Group)
	Predecessor	Arpida AG (SWX: ARPN)
	Industry	food ingredient
	Industry 2	resveratrol
	Person	Waddington, Simon (Evolva 201707–201807 CEO before COO before Abunda Nutrition CEO RESIGNED 7/18)
	Person 2	Hoetmer, Gerard (Corbion 201306 CEO)

	Region	Reinach BL
	Country	Switzerland
	Street	23 Duggingerstr.
	City	4153 Reinach BL
	Tel	+41-61-4852000
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2014-12-31)
	Currency	CHF
	Annual sales	9,600,000 (revenue, total, consolidated (2016) 2016-12-31)
	Profit	-35,800,000 (2016-12-31)
	Cash	47,500,000 (2016-12-31)

		* Document for »About Section«:

		Record changed: 2025-03-16